Article
Immune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I alleles.
Frontiers in immunology - 1 Jan 2022
Walker Andreas, Schwarz Tatjana, Brinkmann-Paulukat Janine, Wisskirchen Karin, Menne Christopher, Alizei Elahe Salimi, Kefalakes Helenie, Theissen Martin, Hoffmann Daniel, Schulze Zur Wiesch Julian, Maini Mala K, Cornberg Markus, Kraft Anke Rm, Keitel Verena, Bock Hans H, Horn Peter A, Thimme Robert, Wedemeyer Heiner, Heinemann Falko M, Luedde Tom, Neumann-Haefelin Christoph, Protzer Ulrike, Timm Jörg
Abstract excerpt
Background and aims: There is growing interest in T cell-based immune therapies for a functional cure of chronic HBV infection including check-point inhibition, T cell-targeted vaccines or TCR-grafted effector cells. All these approaches depend on recognition of HLA class I-presented viral peptides. The HBV core region 18-27 is an immunodominant target of CD8+ T cells and represents the prime target for T...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.